This is a pilot, open label-clinical trial designed to test the toxicity and potential efficacy of a new immunoablative and bone marrow suppressive combination regimen prior (preparative phase) to stem cell transplantation in patients with rapidly progressing cutaneous scleroderma.

Project Start
1999-09-30
Project End
2003-09-29
Budget Start
2000-09-20
Budget End
2001-03-31
Support Year
Fiscal Year
2000
Total Cost
$494,890
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Donnenberg, Albert D; Donnenberg, Vera S (2007) Rare-event analysis in flow cytometry. Clin Lab Med 27:627-52, viii
Hu, Paul Q; Oppenheim, Joost J; Medsger Jr, Thomas A et al. (2006) T cell lines from systemic sclerosis patients and healthy controls recognize multiple epitopes on DNA topoisomerase I. J Autoimmun 26:258-67
Hu, Paul Q; Fertig, Noreen; Medsger Jr, Thomas A et al. (2004) Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis. J Immunol 173:2834-41
Hu, Paul Q; Fertig, Noreen; Medsger Jr, Thomas A et al. (2003) Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 48:1363-73
Meidenbauer, Norbert; Hoffmann, Thomas K; Donnenberg, Albert D (2003) Direct visualization of antigen-specific T cells using peptide-MHC-class I tetrameric complexes. Methods 31:160-71